Compare Stocks: COAG, LGND, CGON, and SRRK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$67.38 -1.4%	$74.10	$35.80 ▼ $80.97	$5.97B	0.28	980,794 shs	1.54 million shs
COAG Hemab Therapeutics	$31.11 +0.2%	$44.44	$23.00 ▼ $55.42	$1.45B	N/A	606,025 shs	354,147 shs
LGND Ligand Pharmaceuticals	$302.96 +0.1%	$291.44	$175.89 ▼ $326.63	$6.04B	1.14	259,162 shs	179,227 shs
SRRK Scholar Rock	$46.81 +1.4%	$52.26	$27.07 ▼ $61.76	$5.62B	0.61	2.20 million shs	1.24 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-1.42%	+0.34%	-9.67%	-4.24%	+70.76%
COAG Hemab Therapeutics	+0.16%	-10.45%	-30.40%	+0.35%	+3,110,999,900.00%
LGND Ligand Pharmaceuticals	+0.07%	+0.48%	+5.59%	-5.19%	+69.19%
SRRK Scholar Rock	+1.41%	-3.74%	-16.56%	-14.70%	+34.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$67.38 -1.4%	$74.10	$35.80 ▼ $80.97	$5.97B	0.28	980,794 shs	1.54 million shs
COAG Hemab Therapeutics	$31.11 +0.2%	$44.44	$23.00 ▼ $55.42	$1.45B	N/A	606,025 shs	354,147 shs
LGND Ligand Pharmaceuticals	$302.96 +0.1%	$291.44	$175.89 ▼ $326.63	$6.04B	1.14	259,162 shs	179,227 shs
SRRK Scholar Rock	$46.81 +1.4%	$52.26	$27.07 ▼ $61.76	$5.62B	0.61	2.20 million shs	1.24 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-1.42%	+0.34%	-9.67%	-4.24%	+70.76%
COAG Hemab Therapeutics	+0.16%	-10.45%	-30.40%	+0.35%	+3,110,999,900.00%
LGND Ligand Pharmaceuticals	+0.07%	+0.48%	+5.59%	-5.19%	+69.19%
SRRK Scholar Rock	+1.41%	-3.74%	-16.56%	-14.70%	+34.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.73	Moderate Buy	$87.78	30.27% Upside
COAG Hemab Therapeutics	2.57	Moderate Buy	$51.40	65.22% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$337.89	11.53% Upside
SRRK Scholar Rock	2.94	Moderate Buy	$66.75	42.60% Upside

Current Analyst Ratings Breakdown

Latest COAG, LGND, CGON, and SRRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	COAG Hemab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/25/2026	LGND Ligand Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$345.00
9/24/2026	SRRK Scholar Rock	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$76.00 ➝ $77.00
9/24/2026	LGND Ligand Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$358.00
9/23/2026	LGND Ligand Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$390.00 ➝ $397.00
9/21/2026	LGND Ligand Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/21/2026	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$70.00
9/21/2026	SRRK Scholar Rock	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$63.00 ➝ $70.00
9/15/2026	SRRK Scholar Rock	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/15/2026	SRRK Scholar Rock	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$72.00
9/15/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$64.00

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$6.23M	958.99	N/A	N/A	$9.33 per share	7.22
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	$268.09M	22.53	$7.86 per share	38.56	$51.68 per share	5.86
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
COAG Hemab Therapeutics	N/A	-$24.78	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	$124.45M	$9.35	32.40	36.28	2.44	67.88%	20.06%	11.68%	11/5/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	11/13/2026 (Estimated)

Latest COAG, LGND, CGON, and SRRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	COAG Hemab Therapeutics	-$0.63	-$0.80	-$0.17	-$0.80	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
COAG Hemab Therapeutics	N/A	35.85	35.85
LGND Ligand Pharmaceuticals	1.16	31.18	30.96
SRRK Scholar Rock	0.77	7.02	7.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
COAG Hemab Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
COAG Hemab Therapeutics	N/A
LGND Ligand Pharmaceuticals	5.60%
SRRK Scholar Rock	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
COAG Hemab Therapeutics	59	46.71 million	N/A	N/A
LGND Ligand Pharmaceuticals	47	19.94 million	18.82 million	Optionable
SRRK Scholar Rock	289	121.79 million	109.24 million	Optionable

COAG, LGND, CGON, and SRRK Headlines

Recent News About These Companies

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

September 30 at 9:56 AM | prnewswire.com

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

September 28, 2026 | finance.yahoo.com

Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says

September 25, 2026 | finance.yahoo.com

Scholar Rock (NASDAQ:SRRK) Trading 6% Higher After Analyst Upgrade

September 24, 2026 | americanbankingnews.com

How Scholar Rock Holding Corporation (SRRK) Affects Rotational Strategy Timing

September 23, 2026 | news.stocktradersdaily.comN

Scholar Rock (NASDAQ:SRRK) Shares Up 6% Following Analyst Upgrade

September 22, 2026 | marketbeat.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 21, 2026

September 22, 2026 | biospace.comB

Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

September 21, 2026 | marketbeat.com

Bank of America Corp DE Takes $53.47 Million Position in Scholar Rock Holding Corporation $SRRK

September 21, 2026 | marketbeat.com

Scholar Rock Holding (SRRK) Receives a Buy from Piper Sandler

September 17, 2026 | theglobeandmail.com

Scholar Rock (NASDAQ:SRRK) Raised to Strong-Buy at Jefferies Financial Group

September 17, 2026 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Scholar Rock

September 17, 2026 | marketbeat.com

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

September 16, 2026 | insidermonkey.com

Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions

September 15, 2026 | finance.yahoo.com

Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says

September 15, 2026 | finance.yahoo.com

Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

September 15, 2026 | seekingalpha.com

Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy

September 15, 2026 | msn.com

Scholar Rock (NASDAQ:SRRK) Shares Down 7.1% - Here's What Happened

September 15, 2026 | marketbeat.com

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

September 15, 2026 | benzinga.com

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets

September 14, 2026 | finance.yahoo.com

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

September 14, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG, LGND, CGON, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

$67.38 -0.97 (-1.42%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$67.44 +0.06 (+0.09%)

As of 10/2/2026 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Hemab Therapeutics NASDAQ:COAG

$31.11 +0.05 (+0.16%)

As of 10/2/2026 04:00 PM Eastern

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.

Ligand Pharmaceuticals NASDAQ:LGND

$302.96 +0.22 (+0.07%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$303.06 +0.10 (+0.03%)

As of 10/2/2026 07:30 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Scholar Rock NASDAQ:SRRK

$46.81 +0.65 (+1.41%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$47.05 +0.24 (+0.51%)

As of 10/2/2026 07:30 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COAG, LGND, CGON, and SRRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COAG, LGND, CGON, and SRRK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COAG, LGND, CGON, and SRRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG, LGND, CGON, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

Hemab Therapeutics NASDAQ:COAG

Ligand Pharmaceuticals NASDAQ:LGND

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COAG, LGND, CGON, and SRRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COAG, LGND, CGON, and SRRK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COAG, LGND, CGON, and SRRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG, LGND, CGON, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

Hemab Therapeutics NASDAQ:COAG

Ligand Pharmaceuticals NASDAQ:LGND

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools